Exploring the therapeutic potentials of iNKT cells for anti-HBV treatment

Pathogens

Volumn 3, Issue 3, 2014, Pages 563-576

  Lawrenczyk, Agnieszka ^a,b   Kim, Seil ^a   Wen, Xiangshu ^a   Xiong, Ran ^a   Yuan, Weiming ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b California Institute for Biomedical Research   (United States)

Author keywords

Antivirals; HBV; Humanized mice; Immunotherapy; NKT

Indexed keywords

ALPHA GALCER; ALPHA INTERFERON; FAS LIGAND; GAMMA INTERFERON; GLYCOSPHINGOLIPID; GRANZYME B; HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; LIGAND; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; PROGRAMMED DEATH 1 LIGAND 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CD1D RESTRICTED INVARIANT NATURAL KILLER T CELL; CD8+ T LYMPHOCYTE; DENDRITIC CELL; HELPER CELL; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; KUPFFER CELL; LIVER CELL; NATURAL KILLER T CELL; NONHUMAN; REVIEW; STELLATE CELL; TH1 CELL;

EID: 84938907095     PISSN: None     EISSN: 20760817     Source Type: Journal    
DOI: 10.3390/pathogens3030563     Document Type: Review

References (53)

1. Arzumanyan, A.; Reis, H.M.; Feitelson, M.A. Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma. Nat. Rev. Cancer 2013, 13, 123-135.
2. Vierling, J.M. The immunology of hepatitis B. Clin. Liver Dis. 2007, 11, 727-759.
3. Shi, Y.-H. Molecular characteristics and stages of chronic hepatitis B virus infection. World J. Gastroenterol. 2009, 15, 3099-3105.
4. Lee, W.M. Hepatitis B Virus Infection. N. Engl. J. Med. 1997, 337, 1733-1745.
5. Rehermann, B. Chronic infections with hepatotropic viruses: Mechanisms of impairment of cellular immune responses. Semin. Liver Dis. 2007, 27, 152-160.
6. Nebbia, G.; Peppa, D.; Maini, M.K. Hepatitis B infection: Current concepts and future challenges. QJM 2012, 105, 109-113.
7. Zhang, Z.; Zhang, J.Y.; Wang, L.F.; Wang, F.S. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. J. Gastroenterol. Hepatol. 2012, 27, 223-230.
8. Chang, J.J.; Lewin, S.R. Immunopathogenesis of hepatitis B virus infection. Immunol. Cell Biol. 2007, 85, 16-23.
9. Op den Brouw, M.L. Dendritic Cells in Hepatitis B Virus Infection: Host-Pathogen Interaction and Immune Modulation; Eramus Universitiet Rotterdam: Rotterdam, The Netherlands, 2010.
10. Crispe, I.N. Hepatic T cells and liver tolerance. Nat. Rev. Immunol. 2003, 3, 51-62.
11. Visvanathan, K.; Skinner, N.A.; Thompson, A.J.; Riordan, S.M.; Sozzi, V.; Edwards, R.; Rodgers, S.; Kurtovic, J.; Chang, J.; Lewin, S.; et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007, 45, 102-110.
12. Stacy, A.R.; Diggle, S.P.; Whiteley, M. Rules of engagement: Defining bacterial communication. Curr. Opin. Microbiol. 2012, 15, 155-161.
13. Szabo, G.; Mandrekar, P.; Dolganiuc, A. Innate immune response and hepatic inflammation. Semin. Liver Dis. 2007, 27, 339-350.
14. Bertoletti, A.; Ferrari, C. Innate and adaptive immune responses in chronic hepatitis B virus infections: Towards restoration of immune control of viral infection. Gut 2012, 61, 1754-1764.
15. Bertoletti, A.; Gehring, A.J. The immune response during hepatitis B virus infection. J. Gen. Virol. 2006, 87, 1439-1449.
16. Chisari, F.V.; Isogawa, M.; Wieland, S.F. Pathogenesis of hepatitis B virus infection. Pathol. Biol. (Paris) 2010, 58, 258-266.
17. Guidotti, L.G.; Rochford, R.; Chung, J.; Shapiro, M.; Purcell, R.; Chisari, F.V. Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection. Science 1999, 284, 825-829.
18. Boni, C.; Fisicaro, P.; Valdatta, C.; Amadei, B.; di Vincenzo, P.; Giuberti, T.; Laccabue, D.; Zerbini, A.; Cavalli, A.; Missale, G.; et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 2007, 81, 4215-4225.
19. Wynn, T.A. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat. Rev. Immunol. 2004, 4, 583-594.
20. Hernandez-Gea, V.; Friedman, S.L. Pathogenesis of Liver Fibrosis. Annu. Rev. Pathol. 2011, 6, 425-456.
21. Ito, H.; Ando, K.; Ishikawa, T.; Nakayama, T.; Taniguchi, M.; Saito, K.; Imawari, M.; Moriwaki, H.; Yokochi, T.; Kakumu, S.; et al. Role of Valpha14+ NKT cells in the development of Hepatitis B virus-specific CTL: Activation of Valpha14+ NKT cells promotes the breakage of CTL tolerance. Int. Immunol. 2008, 20, 869-879.
22. Chikuma, S.; Terawaki, S.; Hayashi, T.; Nabeshima, R.; Yoshida, T.; Shibayama, S.; Okazaki, T.; Honjo, T. PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. J. Immunol. 2009, 182, 6682-6689.
23. Gehring, A.J.; Ho, Z.Z.; Tan, A.T.; Aung, M.O.; Lee, K.H.; Tan, K.C.; Lim, S.G.; Bertoletti, A. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2009, 137, 682-690.
24. Peng, G.; Li, S.; Wu, W.; Sun, Z.; Chen, Y.; Chen, Z. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology 2008, 123, 57-65.
25. Sanchez-Fueyo, A.; Tian, J.; Picarella, D.; Domening, C.; Zheng, X.X.; Sabatos, C.A.; Manlongat, N.; Bender, O.; Kamradt, T.; Kuchroo, V.K.; et al. Tim-3 inhibits T helper type 1-mediated auto-and alloimmune responses and promotes immunological tolerance. Nat. Immunol. 2003, 4, 1093-1101.
26. Wu, W.; Shi, Y.; Li, J.; Chen, F.; Zheng, M. Tim-3 expression on peripheral T cell subsets correlates with disease progression in hepatitis B infection. Virol. J. 2011, 8, doi:10.1186/1743-422X-8-113.
27. Rong, Y.H.; Wan, Z.H.; Song, H.; Li, Y.L.; Zhu, B.; Zang, H.; Zhao, Y.; Liu, H.L.; Zhang, A.M.; Xiao, L.; et al. Tim-3 expression on peripheral monocytes and CD3+CD16/CD56+natural killer-like T cells in patients with chronic hepatitis B. Tissue Antigens 2014, 83, 76-81.
28. Bendelac, A.; Savage, P.B.; Teyton, L. The biology of NKT cells. Annu. Rev. Immunol. 2007, 25, 297-336.
29. Halder, R.C.; Aguilera, C.; Maricic, I.; Kumar, V. Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J. Clin. Investig. 2007, 117, 2302-2312.
30. Park, O.; Jeong, W.I.; Wang, L.; Wang, H.; Lian, Z.X.; Gershwin, M.E.; Gao, B. Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology 2009, 49, 1683-1694.
31. Wang, X.F.; Lei, Y.; Chen, M.; Chen, C.B.; Ren, H.; Shi, T.D. PD-1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication. J. Viral Hepat. 2013, 20, 27-39.
32. Pellicci, D.G.; Patel, O.; Kjer-Nielsen, L.; Pang, S.S.; Sullivan, L.C.; Kyparissoudis, K.; Brooks, A.G.; Reid, H.H.; Gras, S.; Lucet, I.S.; et al. Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. Immunity 2009, 31, 47-59.
33. Ambrosino, E.; Berzofsky, J.A.; Terabe, M. Regulation of tumor immunity the role of NKT cells. 2008, 8, 725-734.
34. Berzins, S.P.; Smyth, M.J.; Baxter, A.G. Presumed guilty: Natural killer T cell defects and human disease. Nat. Rev. Immunol. 2011, 11, 131-142.
35. Xu, Z.; Yen, T.S.B.; Wu, L.; Madden, C.R.; Tan, W.; Slagle, B.L.; Ou, J.H. Enhancement of Hepatitis B Virus Replication by Its X Protein in Transgenic Mice. J. Virol. 2002, 76, 2579-2584.
36. Guidotti, L.G.; Matzke, B.; Schaller, H.; Chisari, F.V. High-Level HBV replication in Transgenic Mice. J Virol. 1995, 69, 6158-6169.
37. Kakimi, K.; Guidotti, L.G.; Koezuka, Y.; Chisari, F.V. Natural Killer T cell activation inhibits hepatitis b virus replication in vivo. J. Exp. Med. 2000, 192, 921-930.
38. Matsuda, J.L.; Mallevaey, T.; Scott-Browne, J.; Gapin, L. CD1d-restricted iNKT cells, the Swiss-Army knife of the immune system. Curr. Opin. Immunol. 2008, 20, 358-368.
39. La Cava, A.; Van Kaer, L.; Fu Dong, S. CD4+CD25+ Tregs and NKT cells: Regulators regulating regulators. Trends Immunol. 2006, 27, 322-327.
40. Oh, K.H.; Lee, C.; Lee, S.W.; Jeon, S.H.; Park, S.-H.; Seong, R.H.; Hong, S. Activation of natural killer T cells inhibits the development of induced regulatory T cells via IFNγ. Biochem. Biophys. Res. Commun. 2011, 411, 599-606.
41. Juno, J.A.; Keynan, Y. Fowke KR Invariant NKT Cells: Regulation and Function during Viral Infection. PLoS Pathog. 2012, 8, e1002838.
42. Wen, X.; Rao, P.; Carreno, L.J.; Kim, S.; Lawrenczyk, A.; Porcelli, S.A.; Cresswell, P.; Yuan, W. Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted natural killer T cells. Proc. Natl. Acad. Sci. USA 2013, 110, 2963-2968.
43. Woltman, A.M.; Ter Borg, M.J.; Binda, R.S.; Sprengers, D.; von Blomberg, B.M.; Scheper, R.J.; Hayashi, K.; Nishi, N.; Boonstra, A.; van der Molen, R.; et al. α-Galactosylceramide in chronic hepatitis B infection: Results from a randomized placebo-controlled PhaseI/II trial. Antivir. Ther. 2009, 14, 809-818.
44. McCarthy, C.; Shepherd, D.; Fleire, S.; Stronge, V.S.; Koch, M.; Illarionov, P.A.; Bossi, G.; Salio, M.; Denkberg, G.; Reddington, F.; et al. The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. J. Exp. Med. 2007, 204, 1131-1144.
45. Koch, M.; Stronge, V.S.; Shepherd, D.; Gadola, S.D.; Mathew, B.; Ritter, G.; Fersht, A.R.; Besra, G.S.; Schmidt, R.R.; Jones, E.Y.; et al. The crystal structure of human CD1d with and without alpha-galactosylceramide. Nat. Immunol. 2005, 6, 819-826.
46. Lawrenczyk, A.; Kim, S.; Wen, X.; Xiong, R.; Yuan, W. Unpublished data, 2014.
47. Jiang, X.; Zhang, M.; Lai, Q.; Huang, X.; Li, Y.; Sun, J.; Abbott, W.G.H.; Ma, S.; Hou, J. Restored circulating invariant NKT cells are associated with viral control in patients with chronic hepatitis B. PLoS One 2011, 6, e28871.
48. Shi, T.D.; Zhang, J.M.; Wang, X.F.; Chen, M.; Sun, H.; Chen, C.B.;Ren, H. Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients. Clin. Exp. Med. 2012, 12, 105-113.
49. Golden-Mason, L.; Palmer, B.; Klarquist, J.; Mengshol, J.A.; Castelblanco, N.; Rosen, H.R. (2007) Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J. Virol. 2007, 81, 9249-9258.
50. Reilly, E.C.; Thompson, E.A.; Aspeslagh, S.; Wands, J.R.; Elewaut, D.; Brossay, L. Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection. PLoS One 2012, 7, e37991.
51. Horst, D.; Geerdink, R.; Gram, A.; Stoppelenburg, A.; Ressing, M. Hiding Lipid Presentation: Viral Interference with CD1d-Restricted Invariant Natural Killer T (iNKT) Cell Activation. Viruses 2012, 4, 2379-2399.
52. Mizrahi, M.; Lalazar, G.; Ben Ya'acov, A.; Livovsky, D.M.; Horowitz, Y.; Zolotarov, L.; Adler, R.; Shouval, D.; Ilan, Y. β-Glycoglycosphingolipid-induced augmentation of the anti-HBV immune response is associated with altered CD8 and NKT lymphocyte distribution: A novel adjuvant for HBV vaccination. Vaccine 2008, 26, 2589-2595.
53. Zeissig, S.; Murata, K.; Sweet, L.; Publicover, J.; Hu, Z.; Kaser, A.; Bosse, E.; Iqbal, J.; Hussain, M.M.; Balschun, K.; et al. Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. Nat. Med. 2012, 18, 1060-1068.